A randomized placebo-controlled study has demonstrated no effect of @entity617 in customary dosage on @entity1274 ( @entity1274 ). The aim of the present paper is to analyse a larger @entity1 group by meta-analysis of data from the RCT together with a corresponding material drawn from the Swedish national database for @entity1274 . Data from 192 @entity1 , 18-80  years with @entity1274 , were available. All had an acute @entity393 of at least 30  dB measured as PTA in the three most affected contiguous frequencies. All @entity1 had been enrolled within one week after onset and evaluated by audiograms after 3 months. 45/99 (RCT) and 54/99 (the database) had been treated with @entity617 in tapering doses from 60  mg daily and 42/93 with placebo (RCT) or 51/93 with no treatment (the database). Primary outcome was the mean hearing improvement on day 90 for the different groups. A mean difference of >10  dB improvement was required to demonstrate a treatment effect for @entity617 compared to placebo/no treatment. No significant difference was seen between the @entity617 group and placebo/no treatment (p  =  0.06). Total recovery was 38  % in @entity617 group, 40  % in the placebo and 14  % in the no treatment group. Vertigo at the onset of @entity393 and age at onset had an equal negative prognostic value in all groups and signs of @entity32 had a positive effect. @entity617 in customary dosage does not influence recovery after @entity1274 .

Corticosteroid treatment of XXXX : analysis of an RCT and material drawn from the Swedish national database.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity1274 :: ('MESH:D006319', 'Disease') :: ['idiopathic sudden sensorineural hearing loss', 'ISSNHL'] @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['Prednisolone', 'prednisolone']
@entity1274 :: (MESH:D006319,Disease) :: ['idiopathic sudden sensorineural hearing loss']
